Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 1.00 |
| ▸ | INSR | P06213 | 14/20 | 1.00 |
| ▸ | NPM1 | P06748 | 11/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | RET | P07949 | 1/20 | 0.76 |
| ▸ | IGF1R | P08069 | 1/20 | 0.76 |
| ▸ | MET | P08581 | 1/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.76 |
| ▸ | CDK2 | P24941 | 1/20 | 0.76 |
| ▸ | AKT1 | P31749 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | GSK3B | P49841 | 1/20 | 0.76 |
| ▸ | PLK1 | P53350 | 1/20 | 0.76 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.76 |
| ▸ | BTK | Q06187 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1545609 | 1.00 | ALK (1.00) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL4048849 | 0.94 | ALK (0.88) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL1545885 | 0.92 | ALK (0.86) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL1546055 | 0.92 | ALK (0.85) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL4056789 | 0.92 | ALK (0.85) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL1069403 | 0.91 | ALK (1.00) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL1546389 | 0.91 | ALK (0.84) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL14478221 | 0.90 | ALK (0.84) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL17613290 | 0.90 | ALK (0.81) | ALKINSRNPM1KCNH2CYP3A4 | |
| SCHEMBL1545856 | 0.89 | ALK (0.83) | ALKINSRNPM1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195478-A1 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-19 | — | — | US | disclosed |
| CN-118307674-A | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118236374-A | Methods of modulating TIGIT and PD-1 signaling pathways using 1,2, 4-oxadiazole compounds | 奥瑞基尼肿瘤有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-110785187-B | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-111263767-B | Cyclic dinucleotides as stimulators of interferon gene modulators | 北京轩义医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-110382515-B | Modified cyclic dinucleotide compounds | 勃林格殷格翰国际有限公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-109843903-B | Cyclic dinucleotide compounds | 勃林格殷格翰国际有限公司 | 2023-01-24 | — | — | CN | disclosed |
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | disclosed |
| EP-4031578-A1 | ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| US-20220185883-A1 | METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2022-06-16 | — | — | US | disclosed |
| CN-114502590-A | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114272371-A | Combination therapy comprising anti-PD-1 antibody molecules | 诺华股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195478-A1 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | PDCD1, PDCD1LG2, CD274 | ALK 1370/4885INSR 3248/4885NPM1 3777/4885 |
| US-20220185883-A1 | METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, TIMM13, LGALS3BP | ALK 1324/4885INSR 943/4885NPM1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.